Smoking Abstinence and Small Cell Lung Cancer Survival: An Association

Anita Johnston Early, Martin H. Cohen, John D. Minna, Byron E. Fossieck, Daniel C. Ihde, Paul A. Bunn, Mary J. Matthews, Lillian M. Paxton, Robert Makuch

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

The prognostic implications of cigarette smoking were investigated in 112 patients with small cell lung cancer. Twenty had stopped smoking permanently before diagnosis (NS-Prior), 35 had stopped at diagnosis (NS-Dx), and 57 patients continued smoking (S). Therapies included chemotherapy alone or with radiation therapy, with or without thymosin fraction V. The survival difference among the three groups was statistically significant. The NS-Prior patients had the best survival, followed by NS-Dx patients and finally S patients. No S patient has survived, disease free, more than 96 weeks, while three NS-Prior and three NS-Dx patients are disease free 103 to 220 weeks after start of treatment. Thymosin, 60 mg/sq m, yielded survival benefits for the S group only. Continuation of smoking during the treatment of small cell lung cancer was associated with a poor prognosis, while discontinuation of smoking, even at diagnosis, may have beneficial effects on survival.

Original languageEnglish (US)
Pages (from-to)2175-2179
Number of pages5
JournalJAMA - Journal of the American Medical Association
Volume244
Issue number19
DOIs
StatePublished - Nov 14 1980

Fingerprint

Small Cell Lung Carcinoma
Smoking
Survival
Thymosin
Radiotherapy
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Johnston Early, A., Cohen, M. H., Minna, J. D., Fossieck, B. E., Ihde, D. C., Bunn, P. A., ... Makuch, R. (1980). Smoking Abstinence and Small Cell Lung Cancer Survival: An Association. JAMA - Journal of the American Medical Association, 244(19), 2175-2179. https://doi.org/10.1001/jama.1980.03310190027016

Smoking Abstinence and Small Cell Lung Cancer Survival : An Association. / Johnston Early, Anita; Cohen, Martin H.; Minna, John D.; Fossieck, Byron E.; Ihde, Daniel C.; Bunn, Paul A.; Matthews, Mary J.; Paxton, Lillian M.; Makuch, Robert.

In: JAMA - Journal of the American Medical Association, Vol. 244, No. 19, 14.11.1980, p. 2175-2179.

Research output: Contribution to journalArticle

Johnston Early, A, Cohen, MH, Minna, JD, Fossieck, BE, Ihde, DC, Bunn, PA, Matthews, MJ, Paxton, LM & Makuch, R 1980, 'Smoking Abstinence and Small Cell Lung Cancer Survival: An Association', JAMA - Journal of the American Medical Association, vol. 244, no. 19, pp. 2175-2179. https://doi.org/10.1001/jama.1980.03310190027016
Johnston Early, Anita ; Cohen, Martin H. ; Minna, John D. ; Fossieck, Byron E. ; Ihde, Daniel C. ; Bunn, Paul A. ; Matthews, Mary J. ; Paxton, Lillian M. ; Makuch, Robert. / Smoking Abstinence and Small Cell Lung Cancer Survival : An Association. In: JAMA - Journal of the American Medical Association. 1980 ; Vol. 244, No. 19. pp. 2175-2179.
@article{f9c92ac96fae41339b9f2a58ae55725a,
title = "Smoking Abstinence and Small Cell Lung Cancer Survival: An Association",
abstract = "The prognostic implications of cigarette smoking were investigated in 112 patients with small cell lung cancer. Twenty had stopped smoking permanently before diagnosis (NS-Prior), 35 had stopped at diagnosis (NS-Dx), and 57 patients continued smoking (S). Therapies included chemotherapy alone or with radiation therapy, with or without thymosin fraction V. The survival difference among the three groups was statistically significant. The NS-Prior patients had the best survival, followed by NS-Dx patients and finally S patients. No S patient has survived, disease free, more than 96 weeks, while three NS-Prior and three NS-Dx patients are disease free 103 to 220 weeks after start of treatment. Thymosin, 60 mg/sq m, yielded survival benefits for the S group only. Continuation of smoking during the treatment of small cell lung cancer was associated with a poor prognosis, while discontinuation of smoking, even at diagnosis, may have beneficial effects on survival.",
author = "{Johnston Early}, Anita and Cohen, {Martin H.} and Minna, {John D.} and Fossieck, {Byron E.} and Ihde, {Daniel C.} and Bunn, {Paul A.} and Matthews, {Mary J.} and Paxton, {Lillian M.} and Robert Makuch",
year = "1980",
month = "11",
day = "14",
doi = "10.1001/jama.1980.03310190027016",
language = "English (US)",
volume = "244",
pages = "2175--2179",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "19",

}

TY - JOUR

T1 - Smoking Abstinence and Small Cell Lung Cancer Survival

T2 - An Association

AU - Johnston Early, Anita

AU - Cohen, Martin H.

AU - Minna, John D.

AU - Fossieck, Byron E.

AU - Ihde, Daniel C.

AU - Bunn, Paul A.

AU - Matthews, Mary J.

AU - Paxton, Lillian M.

AU - Makuch, Robert

PY - 1980/11/14

Y1 - 1980/11/14

N2 - The prognostic implications of cigarette smoking were investigated in 112 patients with small cell lung cancer. Twenty had stopped smoking permanently before diagnosis (NS-Prior), 35 had stopped at diagnosis (NS-Dx), and 57 patients continued smoking (S). Therapies included chemotherapy alone or with radiation therapy, with or without thymosin fraction V. The survival difference among the three groups was statistically significant. The NS-Prior patients had the best survival, followed by NS-Dx patients and finally S patients. No S patient has survived, disease free, more than 96 weeks, while three NS-Prior and three NS-Dx patients are disease free 103 to 220 weeks after start of treatment. Thymosin, 60 mg/sq m, yielded survival benefits for the S group only. Continuation of smoking during the treatment of small cell lung cancer was associated with a poor prognosis, while discontinuation of smoking, even at diagnosis, may have beneficial effects on survival.

AB - The prognostic implications of cigarette smoking were investigated in 112 patients with small cell lung cancer. Twenty had stopped smoking permanently before diagnosis (NS-Prior), 35 had stopped at diagnosis (NS-Dx), and 57 patients continued smoking (S). Therapies included chemotherapy alone or with radiation therapy, with or without thymosin fraction V. The survival difference among the three groups was statistically significant. The NS-Prior patients had the best survival, followed by NS-Dx patients and finally S patients. No S patient has survived, disease free, more than 96 weeks, while three NS-Prior and three NS-Dx patients are disease free 103 to 220 weeks after start of treatment. Thymosin, 60 mg/sq m, yielded survival benefits for the S group only. Continuation of smoking during the treatment of small cell lung cancer was associated with a poor prognosis, while discontinuation of smoking, even at diagnosis, may have beneficial effects on survival.

UR - http://www.scopus.com/inward/record.url?scp=84944371040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944371040&partnerID=8YFLogxK

U2 - 10.1001/jama.1980.03310190027016

DO - 10.1001/jama.1980.03310190027016

M3 - Article

C2 - 6252357

AN - SCOPUS:84944371040

VL - 244

SP - 2175

EP - 2179

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 19

ER -